Healthy Extracts Inc. and Australian biotechnology firm Gelteq Ltd. entered into a Memorandum of Understanding on February 11 2026 that will see Healthy Extracts manufacture and distribute Gelteq’s proprietary gel‑delivery formulations in the United States. The agreement designates Healthy Extracts as the primary manufacturer, commercial seller, and distributor, while Gelteq retains ownership of its intellectual property and will provide the technical transfer needed to scale production.
The partnership is a strategic shift for Healthy Extracts, positioning the company to capitalize on the growing demand for precision‑dosed nutraceutical delivery systems. By leveraging its existing U.S. manufacturing infrastructure, Healthy Extracts can accelerate the commercial rollout of next‑generation gel‑based supplements and open opportunities for joint development in new markets such as China and other emerging wellness regions. The MoU is a step toward a full Manufacturing & Royalty Agreement, although the final terms and timeline remain undisclosed.
Healthy Extracts’ management highlighted the significance of the deal. CEO Don Swanson said, "This MoU expands our product pipeline with next‑generation gel‑based nutraceuticals and establishes a clear pathway to scalable U.S. manufacturing and commercial execution. We intend to accelerate product rollout, broaden distribution across multiple channels, and support longer‑term international expansion, as well as collaborate on additional product development, strategic commercialization initiatives, and expanded market opportunities over time." Gelteq’s CEO Nathan Givoni added, "This partnership marks a significant step in expanding the reach of our gel‑based technologies. Healthy Extracts brings the manufacturing strength and market presence needed to introduce new gel‑format nutraceuticals at scale."
Financial context underscores the strategic importance of the deal. Healthy Extracts reported a 23% increase in net revenue in Q3 2025, but its gross profit fell 26% year‑over‑year due to supply‑chain and raw‑material cost pressures, resulting in a net loss of $395,000. Gelteq, meanwhile, faces financial challenges, including negative margins and a distressed Altman Z‑Score, though it maintains moderate debt levels and cash‑flow constraints. The partnership builds on a prior logistics and distribution agreement with Healthy Extracts for North America, established in June 2025, and deepens a relationship that has already included purchases of Gelteq‑formulated products.
The collaboration aligns with broader industry trends toward advanced delivery systems that improve efficacy and consumer experience. Gelteq’s gel‑based platform offers enhanced bioavailability, taste masking, and swallowing ease, positioning it to disrupt both nutraceutical and pharmaceutical markets. For Healthy Extracts, the deal expands its product pipeline and leverages its manufacturing capacity, supporting its growth strategy that includes mergers such as the recent integration with Gummy USA and a focus on direct‑to‑consumer sales and subscription models.
The partnership is expected to generate incremental revenue for Healthy Extracts as it scales production and distribution of Gelteq’s formulations. While specific financial projections are not disclosed, the strategic alignment suggests a positive impact on Healthy Extracts’ long‑term growth trajectory and a potential boost to its market share in the precision‑dosed supplement segment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.